Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study.
暂无分享,去创建一个
Thomas J. Wang | O. Melander | C. Newton-Cheh | P. Nilsson | B. Hedblad | G. Engström | M. Persson | M. Magnusson | J. Struck | N. Morgenthaler | A. Jujić
[1] Pedro Lozano. Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.
[2] L. Groop,et al. Plasma Copeptin and the Risk of Diabetes Mellitus , 2010, Circulation.
[3] V. Salomaa,et al. Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes , 2010, PloS one.
[4] K. Nakao,et al. Natriuretic Peptides/cGMP/cGMP-Dependent Protein Kinase Cascades Promote Muscle Mitochondrial Biogenesis and Prevent Obesity , 2009, Diabetes.
[5] J. Struck,et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. , 2009, Journal of the American College of Cardiology.
[6] D. Levy,et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure , 2009, Nature Genetics.
[7] G. Berglund,et al. Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[8] M. Volpe,et al. Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass , 2007, Journal of hypertension.
[9] D. Levy,et al. Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals , 2007, Circulation.
[10] P. Arner,et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue , 2007, Diabetologia.
[11] T. Jørgensen,et al. N-Terminal Pro Brain Natriuretic Peptide Is Inversely Related to Metabolic Cardiovascular Risk Factors and the Metabolic Syndrome , 2005, Hypertension.
[12] D. Siscovick,et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.
[13] N. Moustaid‐Moussa,et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. , 2005, Diabetes.
[14] A. Quyyumi,et al. Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome , 2004, Circulation.
[15] D. Fliser,et al. Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation , 2004, Circulation.
[16] J. Mair,et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. , 2004, Clinical chemistry.
[17] D. Levy,et al. Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.
[18] D Ghigo,et al. Insulin Stimulates Glucose Transport Via Nitric Oxide/Cyclic GMP Pathway in Human Vascular Smooth Muscle Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[19] S. Jacob,et al. Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance , 2003, Diabetes, obesity & metabolism.
[20] Arya M. Sharma,et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. , 2002, Diabetes.
[21] L. Niskanen,et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. , 2001, Diabetes care.
[22] J. Mair,et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. , 2001, Clinica chimica acta; international journal of clinical chemistry.
[23] R. Sarzani,et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients , 1997, Journal of hypertension.
[24] E. Verspohl,et al. Atrial natriuretic peptide (ANP)-induced inhibition of glucagon secretion: Mechanism of action in isolated rat pancreatic islets , 1996, Peptides.
[25] C. Kahn,et al. Cross-talk between the insulin and angiotensin signaling systems. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[26] D. Harrison,et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.
[27] D. Garbers,et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide , 1995, Nature.
[28] O. Smithies,et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension , 1995, Science.
[29] T. Yandle,et al. Biochemistry of natriuretic peptides , 1994, Journal of internal medicine.
[30] Professor Göran Berglund. The Malmö Diet and Cancer Study Design, biological bank and biomarker programme , 1993 .
[31] P. Weidmann,et al. Increase in Circulating Insulin Induced by Atrial Natriuretic Peptide in Normal Humans , 1986, Journal of cardiovascular pharmacology.
[32] S. Yusuf,et al. Effects of Telmisartan on Glucose Levels in People at HighRisk for Cardiovascular Disease but Free FromDiabetes The TRANSCEND study , 2011 .
[33] F. Di Serio,et al. Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010 , 2005, Clinical chemistry and laboratory medicine.
[34] J. Struck,et al. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. , 2004, Clinical chemistry.
[35] E. Bonora,et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.
[36] C. Berne,et al. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats , 1998, Diabetologia.
[37] Minisymposium: The Malmö Diet and Cancer Study. Design, biological bank and biomarker programme. 23 October 1991, Malmo, Sweden. , 1993, Journal of Internal Medicine.
[38] K. Hosoda,et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. , 1992, Endocrinology.